Skip to main content

Agena, HeartGenetics Ink Genetic Testing Comarketing Deal

NEW YORK (GenomeWeb) – Agena Bioscience announced today that it has signed an agreement to market its MassArray Dx system with HeartGenetics' HeartDecode genetic testing software and cardiovascular assays.

The HeartDecode software is designed to generate clinically actionable reports for HeartGenetics' suite of CE-IVD marked genetic testing kits, which include assays to assess individual risk for various cardiovascular conditions such as hereditary thrombophilia and arterial hypertension, as well as tests for clopidogrel, warfarin, and simvastatin pharmacogenetics.

Under the terms of their alliance, HeartGenetics will offer HeartDecode software and assays designed specifically for use with MassArray Dx mass spectrometry-based genetic analysis system, which is CE-IVD marked in Europe and available for research use only in the US.

Additional terms were not disclosed.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.